Oventus: Innovators in Sleep Apnoea Treatment

2018 AGM Presentation
2018 AGM Presentation
Brisbane, Nov 16, 2018 AEST (ABN Newswire) - Oventus Medical Ltd (ASX:OVN) provides the Company's 2018 AGM Presentation.

Summary of key milestones - FY2018

- July 17: O2Vent(TM) W secures FDA clearance

- Sept/Oct 17: Clinical data presented at World Sleep Congress and Sleep DownUnder conference

- Dec 17: Oventus raises $7.6m to support global roll out of products to OSA sufferers

- Apr 18: US team set up to drive adoption in sleep channel

- May 18: Data confirms Oventus' range can treat >75% of OSA sufferers

- Oct 18: O2Vent Optima(TM) registered with Australian TGA

- Oct 18: Released 4 clinical trial results bringing total data collected to 170 patients

Key strategic initiatives of FY2019

- As product development and clinical trials are finalised, Oventus is transitioning from an R&D focused company to a "go to market" / sales oriented company - with a restructured team

- Key parts of manufacturing process being outsourced to enable Oventus to be a "virtual company", while retaining management of data and software design (core to value proposition)

- Sales / marketing of 'Sleep Treatment Platform' shifted to focus on sleep channel

- Building out US team and rolling out US go to market strategy

- Further communicate outstanding clinical evidence which clearly differentiates Oventus as a new treatment modality

- Commercialising and launching products in late stage development, extending the reach of the Oventus treatment platform and reducing COGS

- Reducing fixed costs in business by 15-20% moving forward - significant steps already undertaken in FY2018

To view the full presentation, please visit:
http://abnnewswire.net/lnk/54HKABA9


About Oventus Medical Ltd

Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintain a stable airway with or without nasal CPAP. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O2VentTM is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

For more information on Oventus' Sleep Treatment Platform, please visit http://www.oventus.com

      


Contact

Dr Chris Hart
Managing Director and CEO
M: +61-409-647-496

Jane Lowe
IR Department
M: +61-411-117-774 or
E: jane.lowe@irdepartment.com.au



Related Companies

Oventus Medical Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 108) (Last 30 Days: 1526) 
ANALYTICS: LOGIN HERE

Oventus Medical Ltd NEWS: RECENT VISITS (6539)